Check Cap Ltd (CHEK) was Reiterated by Chardan Capital Markets to “Buy” while Lowering the Price Target of the company shares to $ 4 from a previous price target of $6 . Chardan Capital Markets advised their investors in a research report released on May 20, 2016.
Many Wall Street Analysts have commented on Check Cap Ltd. Shares were Reiterated by Chardan Capital Markets on Mar 16, 2016 to “Buy” and Lowered the Price Target to $ 6 from a previous price target of $7.75 .
Check Cap Ltd closed down -0.3322 points or -13.56% at $2.1178 with 8,347 shares getting traded on Thursday. Post opening the session at $2.3999, the shares hit an intraday low of $2 and an intraday high of $2.3999 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
Check-Cap Ltd. (Check-Cap) is a clinical-stage medical diagnostics company. The Company is engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for colorectal cancer (CRC) screening. The Company’s imaging capsule is designed to create a reconstructed two and three-dimensional image of the colon and to enable detection of clinical polyps. The Company’s imaging capsule consists of an X-ray source and X-ray detectors. The X-ray source is contained in a rotating radiation shield enabling the generation of 360-degree angular scans. The Company’s imaging capsule is swallowed by the patient and propelled by natural motility through the gastrointestinal tract and excreted naturally. Its imaging capsule employs X-rays which allow it to image the lining of the colon even when surrounded by intestinal content.